Skip to Content


Medically reviewed by Last updated on Jul 2, 2020.


(ter KONE a zole)

Index Terms

  • Triaconazole

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Cream, Vaginal:

Terazol 7: 0.4% (45 g [DSC]) [contains cetyl alcohol, polysorbate 80, propylene glycol]

Terazol 3: 0.8% (20 g [DSC]) [contains cetyl alcohol, polysorbate 80, propylene glycol]

Zazole: 0.8% (20 g [DSC])

Generic: 0.4% (45 g); 0.8% (20 g)

Suppository, Vaginal:

Zazole: 80 mg (3 ea [DSC])

Generic: 80 mg (1 ea, 3 ea)

Brand Names: U.S.

  • Terazol 3 [DSC]
  • Terazol 7 [DSC]
  • Zazole [DSC]

Pharmacologic Category

  • Antifungal Agent, Azole Derivative
  • Antifungal Agent, Vaginal


Terconazole is a triazole ketal antifungal agent; involves inhibition of fungal cytochrome P450. Specifically, terconazole inhibits cytochrome P450-dependent 14-alpha-demethylase which results in accumulation of membrane disturbing 14-alpha-demethylsterols and ergosterol depletion.


Suppository: ~70% remains in vaginal area; ~10% is absorbed systemically


Suppository: Urine (3% to 10%); feces (2% to 6%)

Time to Peak

~5 to 10 hours

Half-Life Elimination

6.4 to 8.5 hours

Protein Binding


Special Populations: Gender

Following terconazole administration, absorption varies in hysterectomized subjects (5% to 8% absorption) vs nonhysterectomized subjects (12% to 16% absorption). Other than this, overall absorption is similar in all women.

Use: Labeled Indications

Candidiasis, vulvovaginal: For the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears or cultures.


Hypersensitivity to terconazole or any component of the formulation

Documentation of allergenic cross-reactivity for imidazole antifungals is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Dosing: Adult

Candidiasis, vulvovaginal: Intravaginal:

Vaginal cream 0.4%: Insert 1 applicatorful intravaginally at bedtime for 7 consecutive days.

Vaginal cream 0.8%: Insert 1 applicatorful intravaginally at bedtime for 3 consecutive days.

Vaginal suppository: Insert 1 suppository intravaginally at bedtime for 3 consecutive days.

Note: A longer duration may be necessary in patients with complicated infection (ie, recurrent or severe infection, infection with non-albicans Candida, or infection in an immunocompromised host) (CDC [Workowski 2015]; HHS [OI adult 2020]).

Dosing: Geriatric

Refer to adult dosing.



Vaginal cream: Use applicator provided by manufacturer. Insertion should be as far as possible into the vagina without causing discomfort. Wash applicator after each use; allow to dry thoroughly before putting back together.

Vaginal suppository: Remove foil package prior to use. Insertion should be as far as possible into the vagina without causing discomfort. If the provided applicator is used for insertion, wash and dry thoroughly prior to additional use.


Store at 15°C to 30°C (59°F to 86°F).

Drug Interactions

Progesterone: Antifungal Agents (Vaginal) may diminish the therapeutic effect of Progesterone. Avoid combination

Adverse Reactions

>10%: Central nervous system: Headache

1% to 10%:

Central nervous system: Chills, pain

Gastrointestinal: Abdominal pain

Genitourinary: Dysmenorrhea, vaginal discomfort (burning, irritation, or itching)

Miscellaneous: Fever

<1%, postmarketing, and/or case reports: Anaphylaxis, asthenia, bronchospasm, burning sensation of the penis, dizziness, facial edema, flu-like symptoms (including nausea, vomiting, myalgia, arthralgia, malaise), hypersensitivity, skin rash, toxic epidermal necrolysis, urticaria


Concerns related to adverse effects:

• Dermatologic toxicity: If toxic epidermal necrolysis (TEN) occurs, discontinue therapy; implement supportive care/monitoring. Do not reinstitute therapy.

• Hypersensitivity/anaphylaxis: If anaphylaxis occurs, discontinue therapy; implement supportive care/monitoring. Do not reinstitute therapy.

• Idiosyncratic reactions: If fever, chills, or flu-like symptoms occur, discontinue therapy. Do not reinstitute therapy.

• Irritation: If irritation or sensitization occurs, discontinue use. Do not reinstitute therapy.

Dosage form specific issues:

• Vaginal suppository: The base in the suppository formulation may weaken latex or rubber (condoms or diaphragms); concurrent use is not recommended.

Other warnings/precautions:

• Lack of response: Microbiological studies (KOH smear and/or cultures) should be repeated in patients not responding to terconazole in order to confirm the diagnosis and rule out other pathogens.

Reproductive Considerations

This product may weaken latex condoms and diaphragms (CDC [Workowski 2015]).

Pregnancy Considerations

The rate and extent of absorption are similar in pregnant and nonpregnant patients with vulvovaginal candidiasis. Although the manufacturer recommends that use should be avoided during the first trimester of pregnancy (due to systemic absorption) and that use may be considered in the second or third trimesters if the benefits outweigh risks to the fetus, guidelines state that 7-day topical azole vaginal products are the preferred treatment of vulvovaginal candidiasis in pregnant women (CDC [Workowski 2015].

Patient Education

What is this drug used for?

• It is used to treat vaginal infections.

• It may be given to you for other reasons. Talk with the doctor.

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Headache

• Menstrual pain

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Severe vaginal irritation

• Chills

• Flu-like signs

• Stevens-Johnson syndrome/toxic epidermal necrolysis like red, swollen, blistered, or peeling skin (with or without fever); red or irritated eyes; or sores in mouth, throat, nose, or eyes

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.